Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7049327 | 0.85 | CAPN1 (0.44) | BMP1CAPN1CAPN2FOLH1HTT | |
| SCHEMBL7046334 | 0.82 | CAPN1 (0.46) | BMP1CAPN1CAPN2FOLH1HTT | |
| SCHEMBL7432056 | 0.75 | FOLH1 (0.61) | BMP1FOLH1HTTSIRT2TGM2 | |
| SCHEMBL6447440 | 0.73 | HTT (0.57) | CAPN1CAPN2FOLH1HTTSIRT2 | |
| SCHEMBL6447441 | 0.73 | HTT (0.57) | CAPN1CAPN2FOLH1HTTSIRT2 | |
| SCHEMBL8099794 | 0.72 | TACR1 (0.57) | — | |
| SCHEMBL7044864 | 0.72 | SLC1A3 (0.41) | HTT | |
| SCHEMBL6443882 | 0.72 | HTT (0.56) | CAPN1CAPN2FOLH1HTTSIRT2 | |
| SCHEMBL29072091 | 0.72 | CA1 (0.64) | FOLH1HTTSIRT2 | |
| SCHEMBL29072142 | 0.72 | CA1 (0.64) | FOLH1HTTSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | BMP1 1852/4885CAPN1 56/4885CAPN2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.